Is irisin an anticarcinogenic peptide?

Abstract

Irisin is thought an anti obesity hormone, which regulates body weight and metabolism, including insulin resistance. It is known that obesity is a risk factor in the development of cancer. This study was designed to evaluate whether there is a role of irisin on viability of human prostate cancer cells. In the present study, 0.1, 1, 10 and 100 nM concentrations of irisin were applied to human prostate cancer cells with androgen receptor positive (LNCaP) and androgen receptor negative (DU-145, PC3). Effects of irisin were determined using 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. At the end of study, all concentrations of irisin reduced viability in the three types of prostate cells, but only 10 and 100 nM concentrations of the irisin caused a significant decreases (p<0.05). Consequently, high concentrations of irisin in both androgen receptor positive and androgen receptor negative cell lines reduced cell viability. These results show that the cytotoxic effects of irisin on prostate cancer cells are not dependent on androgen receptor mechanism.